---
layout: default
title: Fulvestrant
parent: 僅模型預測 (L5)
nav_order: 380
evidence_level: L5
indication_count: 10
---

# Fulvestrant
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Fulvestrant: Original Indication Not on File — Predicted for HIV Infectious Disease

## One-Sentence Summary

The evidence pack does not document Fulvestrant's original approved indication or India market license data (0 registrations, not marketed). The TxGNN model predicts it may be effective for **HIV Infectious Disease**, but this direction is currently supported by **0 clinical trials** and only **1 loosely related publication** (which concerns HTLV-1, not HIV itself).

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented in this evidence pack (no India-approved license record; `original_indications` empty) |
| Predicted New Indication | HIV Infectious Disease |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L5 |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data for Fulvestrant is flagged as a data gap in this evidence pack (DG002). Based on evidence embedded elsewhere in the pack (clinical trial titles/summaries under the "multiple endocrine neoplasia" candidate), Fulvestrant is identifiable as a selective estrogen receptor degrader (SERD) used across dozens of hormone receptor-positive (HR+), HER2-negative metastatic breast cancer trials — but no original-indication or India licensing data is present here to confirm this formally for this candidate record.

For the top-ranked prediction, HIV Infectious Disease, the model's own supporting rationale states there is **no direct mechanistic link**. The single literature hit is a cross-omics cohort analysis of HTLV-1-associated myelopathy (HAM) — a different retrovirus and disease from HIV — that only touches HIV tangentially as a comparator within a broader neuroinflammatory/viral-immunology framework. It is not a study of fulvestrant, estrogen-receptor biology, or antiretroviral activity.

Given the absence of any mechanistic, preclinical, or clinical connection between an anti-estrogen SERD and HIV pathophysiology, this prediction should be treated as a pure knowledge-graph signal (high TxGNN score, rank 2154) rather than a biologically grounded hypothesis at this stage.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [40343334](https://pubmed.ncbi.nlm.nih.gov/40343334/) | 2025 | Cross-omics Cohort Analysis (Tier 3; HTLV-1, not HIV) | Research square (preprint) | Multi-cohort (epi)genomic analysis of HTLV-1-associated myelopathy (HAM), a neuroinflammatory disease; current HAM treatment is symptomatic and borrows strategies from HIV-1/MS therapy — HIV is referenced only as a comparator, not as the study subject, and fulvestrant is not mentioned. |

---

## India Market Information

Fulvestrant is currently **not marketed in India** — no licenses are on file (`total_licenses: 0`, `market_status: 未上市`).

---

## Safety Considerations

**Drug Interactions**: A DDI query returned 92 total interactions on record (source: DDInter), though all listed interaction levels are classified as "Unknown" severity. Representative interacting drugs include:

| Interacting Drug | Level | Source |
|---|---|---|
| Pantoprazole | Unknown | ddinter |
| Morphine | Unknown | ddinter |
| Metformin | Unknown | ddinter |
| Omeprazole | Unknown | ddinter |
| Lansoprazole | Unknown | ddinter |
| Prednisone | Unknown | ddinter |
| Simvastatin | Unknown | ddinter |
| Potassium chloride | Unknown | ddinter |
| Ranitidine | Unknown | ddinter |
| Ondansetron | Unknown | ddinter |
| Metronidazole | Unknown | ddinter |
| Famotidine | Unknown | ddinter |
| Acetylsalicylic acid | Unknown | ddinter |
| Palonosetron | Unknown | ddinter |
| Bupropion | Unknown | ddinter |
| Calcium chloride | Unknown | ddinter |
| Metoclopramide | Unknown | ddinter |
| Dexamethasone | Unknown | ddinter |
| Promethazine | Unknown | ddinter |
| Warfarin | Unknown | ddinter |

Key warnings and contraindications are not available in this evidence pack (flagged as a data gap, DG001 — blocking for safety pre-screening). Please refer to the package insert for that information once obtained.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The HIV infectious disease prediction has no supporting clinical trials, no mechanistically relevant literature, and the one available publication concerns a different disease (HTLV-1, not HIV). Evidence level is L5 (model prediction only), and both the drug's original indication/MOA and its India regulatory status are undocumented data gaps — the candidate does not clear even an initial safety screen (DG001 is explicitly blocking).

**To proceed, the following is needed:**
- Fulvestrant's package insert / TFDA-CDSCO label data (key warnings, contraindications) — currently blocking (DG001)
- Verified mechanism of action documentation (DG002)
- Confirmation of Fulvestrant's actual original indication and any India licensing status
- Any preclinical or in vitro data specifically linking estrogen receptor modulation to HIV viral replication or immune response, if such a hypothesis is to be pursued further
- DDI severity grading (current list shows "Unknown" levels for all 92 interactions, which is not actionable for risk assessment)
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

